BGI’s Real-time Fluorescent RT-PCR Kit for Detecting SARS-CoV-2 is Registered under MHRA and CTDA in the UK

The Real-time Fluorescent RT-PCR Kit for Detecting SARS-CoV-2 has recently been registered under the Medicines and Healthcare products Regulatory Agency (MHRA) and obtained the Coronavirus Test Device Approval (CTDA) in the UK.

The kit is a qualitative in vitro nucleic acid amplification assay designed for highly sensitive detection of SARS-CoV-2, using reverse transcription PCR. Both throat swab and nasopharyngeal swab samples are acceptable. It is applicable to suspects of COVID-19, suspicious clustering cases, and those under investigation.

 

With the registration and approval, BGI is committed to contributing to the continual fight against COVID-19 across the UK.

One Response

Comments are closed.